FrancophonIA/ELRC3.0 huggingface dataset:
English: In vitro, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin.
Maltese: In vitro, l-inibizzjoni ta' HMG-CoA reductase permezz ta' metaboliti ortho- u parahydroxylated hija ekwivalenti għal dik ta' atorvastatin.
English: In a multicenter 8 week open-label compassionate-use study with an optional extension phase of variable length, 335 patients were enrolled, 89 of which were identified as homozygous familial hypercholesterolaemia patients.
Maltese: Fi studju għal użu ta' kompassjoni open-label b'aktar minn ċentru wieħed ta' 8 ġimgħat bl-għażla ta' fażi ta' estensjoni b'tul varjabbli, ħadu sehem 335 pazjent, li 89 minnhom kienu identifikati bħala pazjenti b'iperkolesterolemija omożigotika familjali.
English: − Atorvastatin must be discontinued if clinically significant elevation of CK levels (> 10 x ULN) occur, or if rhabdomyolysis is diagnosed or suspected.
Maltese: Atrovastatin għandu jitwaqqaf jekk ikun hemm żieda klinikament sinifikanti tal-livelli CK (> 10 x ULN), jew jekk tiġi dijanjostikata jew suspettata rhabdomyolysis.
English: Prevention of cardiovascular events in patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.
Maltese: Il-prevenzjoni ta' avvenimenti kardjovaskulari f'pazjenti li huma meqjusa li għandhom riskju għoli talewwel avveniment kardjovaskulari (ara sezzjoni 5.1), bħala żieda għal korrezzjoni ta' fatturi ta' riskju oħrajn.
English: Reductions in total-C, LDL-C, and apolipoprotein B have been proven to reduce risk for cardiovascular events and cardiovascular mortality.
Maltese: Ingħatat prova li t-tnaqqis fit-total-C, LDL-C u l-apolipoproteina B inaqqas ir-riskju ta' avvenimenti kardjovaskulari u mewt kardjovaskulari.
English: 10 mg OD for 28 days
Maltese: 10 mg OD għal 28 jum darbiet
English: Common side effects (affects 1 to 10 users in 100) include:
Maltese: Effetti sekondarji komuni (jaffettwaw minn 1 sa 10 utenti minn kull 100) jinkludu:
English: Hepatic insufficiency: Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16-fold in Cmax and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Child-Pugh B).
Maltese: Il-konċentrazzjonijiet ta' atorvastatin u tal-metaboliti attivi tiegħu fil-plażma jiżdiedu b'mod notevoli (b'madwar 16-il darba fis-Cmax u b'madwar 11-il darba fl-AUC) f'pazjenti li jkollhom mard alkoħoliku kroniku fil-fwied (Child-Pugh B).
English: Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalization, indicating a risk reduction by 16% (p=0.048).
Maltese: It-trattament b'atorvastatin 80 mg/ġurnata żied il-ħin sas-seħħ tal-endpoint primarju kombinat, definit bħala l-mewt minn kwalunkwe kawża, MI mhux fatali, arrest kardijaku risuxxitat, jew anġina pektoris b'evidenza ta' iskemija mijokardijaka li kienet teħtieġ dħul l-isptar, li jindika tnaqqis fir-riskju ta' 16% (p=0.048).
English: Grapefruit Juice, 240 mL OD * 40 mg, SD ↑ 37% Concomitant intake of large quantities of grapefruit juice and atorvastatin is not recommended.
Maltese: 40 mg SD ↑ 37% It-teħid fl-istess ħin ta' kwantitajiet kbar ta' meraq talgrejpfrut u atorvastatin mhuwiex irrakkomandat.
English: Rare side effects (affects 1 to 10 users in 10,000) include:
Maltese: Effetti sekondarji rari (jaffettwaw minn 1 sa 10 utenti minn kull 10,000) jinkludu:
English: This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018).
Maltese: Dan kien dovut prinċipalment għal tnaqqis ta' 26% fid-dħul mill-ġdid l-isptar għal anġina pectoris b'evidenza ta' iskemija mijokardijaka (p=0.018).
English: Triglycerides and cholesterol in the liver are incorporated into very lowdensity lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues.
Maltese: Trigliċeridi u kolesterol fil-fwied huma inkorporati f'lipoproteini b'densità baxxa ħafna (VLDL) u rilaxxati fil-plażma biex jitwasslu għat-tessuti periferali.
English: It is possible that the net risk of stroke is increased in patients with prior lacunar infarct who receive atorvastatin 80 mg/day.
Maltese: Huwa possibbli li r-riskju nett ta' puplesija jiżdied filpazjenti b'infart lakunari preċedenti li jingħataw 80 mg/ġurnata.
English: − Situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)
Maltese: Sitwazzjonijiet fejn tista' sseħħ żieda fil-livelli fil-plażma, bħal pereżempju interazzjonijiet (ara sezzjoni 4.5) u popolazzjonijiet speċjali inkluż subpopolazzjonijiet ġenetiċi (ara sezzjoni 5.2)
English: The risk of muscle related side effects e.g rhabdomyolysis is known to increase when certain medicines are taken at the same time (see Section 2 “Taking other medicines”).
Maltese: Rhabdomyolysis, huwa magħruf li jiżdied meta ċerti mediċini jittieħdu fl-istess ħin (ara Sezzjoni 2 “Meta tieħu mediċini oħra”).
English: Low-density lipoprotein (LDL) is formed from VLDL and is catabolized primarily through the receptor with high affinity to LDL (LDL receptor).
Maltese: Il-lipoproteina b'densità baxxa (LDL) hija ffurmata minn VLDL u primarjament hi katabolizzata permezz tar-riċettur b'affinità għolja għal LDL (riċettur LDL).
English: Very rare: anaphylaxis.
Maltese: Rari ħafna: anafilassi.
English: The use of fibrates alone is occasionally associated with muscle related events, including rhabdomyolysis.
Maltese: L-użu ta' fibrates waħedhom kultant huwa assoċjat ma' avvenimenti relatati mal-muskoli, inkluż rhabdomyolysis.
English: 10 mg OD for 4 weeks
Maltese: 10 mg OD għal 4t ijiem darbiet
English: 40 mg OD for 4 days
Maltese: 40 mg OD għal 4t ijiem darbiet
English: You should maintain a standard cholesterol lowering diet during treatment.
Maltese: Waqt il-kura għandek iżżomm dieta standard għattnaqqis tal-kolesterol.
English: OD = once daily; SD = single dose; BID = twice daily; QID = four times daily
Maltese: BID = darbtejn kuljum; QID = erba' darbiet kuljum
English: Patients with rare hereditary problems of galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.
Maltese: Pazjenti bi problemi ereditarji rari ta' intolleranza għal galactose, b'defiċjenza għal-lactose tip Lapp jew li ma jassorbux glucose-galactose m'għandhomx jieħdu din ilmediċina.
English: In the Reversing Atherosclerosis with Aggressive Lipid- Lowering Study (REVERSAL), the effect of intensive lipid lowering with atorvastatin 80 mg and standard degree of lipid lowering with pravastatin 40 mg on coronary atherosclerosis was assessed by intravascular ultrasound (IVUS), during angiography, in patients with coronary heart disease.
Maltese: Fl-Istudju dwar it-Titjib tal-Aterosklerożi bi Tbaxxija Aggressiva tal-Lipidi (REVERSAL), l-effett tattbaxxija intensiva tal-lipidi b'atorvastatin 80 mg u l-livell standard ta' tbaxxija tal-lipidi bi pravastatin 40 mg fuq l-aterosklerożi koronarja ġie valutat permezz ta' ultrasound intravaskulari (IVUS), waqt anġjografija, f'pazjenti li kellhom mard tal-qalb koronarju.
English: All cause mortality was 15.6% (7/45) for atorvastatin versus 10.4% (5/48) in the subgroup of patients with prior hemorrhagic stroke.
Maltese: 6% (7/45) għal atorvastatin kontra 10.
English: The concurrent use of atorvastatin and fusidic acid is not recommended, therefore, temporary suspension of atorvastatin may be considered during fusidic acid therapy (see section 4.5).
Maltese: L-użu fl-istess ħin ta' atrovastatin u fusidic acid mhuwiex irrakkomandat, għalhekk, tista' tiġi ikkunsidrata t-twaqqif temporanju ta' atrovastatin waqt terapija b'fusidic acid (ara sezzjoni 4.5).
English: Effect of co-administered medicinal products on atorvastatin
Maltese: Effetti ta' prodotti mediċinali mogħtija flimkien ma' atorvastatin
English: Concomitant administration of atorvastatin with inducers of cytochrome P450 3A (e.g. efavirenz, rifampin, St. John's Wort) can lead to variable reductions in plasma concentrations of atorvastatin.
Maltese: L-amministrazzjoni fl-istess ħin ta' atorvastatin ma' inducers ta' cytochrome P450 3A (eż. efavirenz, rifampin, St.
English: Transport protein inhibitors
Maltese: Inibituri tal-proteini tal-ġarr
English: Study results were obtained with the 80 mg dose strength.
Maltese: Id-doża massima hija ta' 80 mg kuljum.
English: LIPITOR and associated names (see Annex I) 10 mg film-coated tablets LIPITOR and associated names (see Annex I) 20 mg film-coated tablets LIPITOR and associated names (see Annex I) 40 mg film-coated tablets LIPITOR and associated names (see Annex I) 80 mg film-coated tablets
Maltese: LIPITOR u l-ismijiet assoċjati (ara Anness I) 10 mg pilloli miksijin b'rita LIPITOR u l-ismijiet assoċjati (ara Anness I) 20 mg pilloli miksijin b'rita LIPITOR u l-ismijiet assoċjati (ara Anness I) 40 mg pilloli miksijin b'rita LIPITOR u l-ismijiet assoċjati (ara Anness I) 80 mg pilloli miksijin b'rita [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: From these 89 patients, the mean percent reduction in LDL-C was approximately 20%.
Maltese: Minn dawn id-89 pazjent, il-perċentwal medju ta' tnaqqis flLDL-C kien ta' bejn wieħed u ieħor 20%.
English: Each film-coated tablet contains 80 mg atorvastatin (as atorvastatin calcium trihydrate).
Maltese: Kull pillola miksija b'rita fiha 80 mg atorvastatin (bħala atorvastatin calcium trihydrate).
English: • gynecomastia (breast enlargement in men and women).
Maltese: • ginekomastja (tkabbir tas-sider fl-irġiel u n-nisa).
English: 10 mg, SD ↑ 33%^ Lower maximum dose and clinical monitoring of these patients is recommended.
Maltese: 10 mg SD ↑ 33%^ Hija rrakkomandata doża massima aktar baxxa kif ukoll monitoraġġ kliniku ta' dawn ilpazjenti
English: Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days
Maltese: Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14-il jum20 mg OD għal 4t ijiem darbiet
English: The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin.
Maltese: Ir-riskju ta' dawn l-avvenimenti jista' jiżdied bl-użu fl-istess ħin ta' derivattivi tal-fibric acid u atorvastatin.
English: The dose may be increased to 80 mg daily, according to the response and tolerability.
Maltese: Id-doża tista' tiżdied sa 80 mg kuljum, skont ir-rispons u t-tollerabilità.
English: Gender: Concentrations of atorvastatin and its active metabolites in women differ from those in men (Women: approx. 20% higher for Cmax and approx. 10% lower for AUC).
Maltese: Il-konċentrazzjonijiet ta' atorvastatin u tal-metaboliti attivi tiegħu fin-nisa huma differenti minn dawk fl-irġiel (Nisa: Cmax madwar 20% ogħla u AUC madwar 10% aktar baxxi ).
English: Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for {PRODUCT NAME}.
Maltese: Skont dejta minn studji kliniċi u esperjenza estensiva wara t-tqegħid fis-suq, it-tabella li ġejja tippreżenta l-profil ta' reazzjonijiet avversi għal {ISEM
English: • Breathing problems including persistent cough and/or shortness of breath or fever
Maltese: • Problemi tan-nifs fosthom sogħla persistenti u/jew qtugħ ta' nifs jew deni
English: The absolute and relative risk reduction effect of atorvastatin was as follows:
Maltese: L-effett ta' tnaqqis assolut u relattiv fir-riskju b'atorvastatin kien hekk:
English: ↑ 8.7 fold
Maltese: TAGĦRIF
English: All patients had at least 3 of the pre-defined cardiovascular risk factors: male gender, age ≥55 years, smoking, diabetes, history of CHD in a first-degree relative, TC:HDL-C >6, peripheral vascular disease, left ventricular hypertrophy, prior cerebrovascular event, specific ECG abnormality, proteinuria/albuminuria.
Maltese: HDL-C >6, mard vaskulari periferali, ipertrofija ventrikolari tax-xellug, episodju ċerebrovaskulari preċedenti, anormalità speċifika tal-ECG, proteinurja/albuminurja.
English: Amlodipine 10 mg, single dose 80 mg, SD ↑ 18% No specific recommendation.
Maltese: Amlodipine 10 mg, doża waħda
English: SLOC1B1 polymorphism: Hepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter.
Maltese: It-teħid epatiku tal-inibituri kollha ta' HMG-CoA reductase fosthom atorvastatin, jinvolvi t-trasportatur OATP1B1.
English: Paediatric use
Maltese: FARMAĊEWTIKU
English: Uncommon side effects (affects 1 to 10 users in 1000) include:
Maltese: Effetti sekondarji mhux komuni (jaffettwaw minn 1 sa 10 utenti minn kull 1000) jinkludu:
English: Levels above 10 times the normal upper range occurred in 0.4% {PRODUCT NAME}-treated patients (see section 4.4).
Maltese: Livelli ogħla minn 10 darbiet aktar mill-firxa normali ta' fuq seħħew f'0.4% tal-pazjenti trattati b'{ISEM
English: In a clinical study in patients receiving chronic warfarin therapy, coadministration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing which returned to normal within 15 days of atorvastatin treatment.
Maltese: Fi studju kliniku fuq pazjenti li kienu qegħdin jirċievu terapija kronika b'warfarin, l-għoti fl-istess ħin ta' atorvastatin 80 mg kuljum ma' warfarin ikkawża tnaqqis żgħir ta' madwar 1.7 sekondi fil-ħin prothrombin matul l-ewwel 4t ijiem ta' dożaġġ, li rritorna għan-normal fi żmien 15-il ġurnata ta' kura b'atorvastatin.
English: − Renal impairment
Maltese: Tqala u treddigħ
English: Efavirenz 600 mg OD, 14 days 10 mg for 3 days ↓ 41% No specific recommendation.
Maltese: 600 mg OD, 14-il jum 10 mg għal 3 ijiem
English: At atorvastatin doses exceeding 40 mg, clinical monitoring of these patients is recommended.
Maltese: Bid-dożi ta' atorvastatin li jaqbżu l-40 mg, huwa rrakkomandat li l-pazjenti jiġu mmonitorjati klinikament.
English: Hepatic impairment {PRODUCT NAME} should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2).
Maltese: TAL-PRODOTT} għandu jintuża b'kawtela f'pazjenti b'indeboliment tal-fwied (ara sezzjonijiet 4.4 u 5.2).
English: • rash, skin rash and itching, hives, hair loss
Maltese: • raxx, raxx u ħakk fil-ġilda, ħorriqija, telf tax-xagħar
English: {PRODUCT NAME} is contraindicated during pregnancy (see section 4.3).
Maltese: TAL-PRODOTT} huwa kontraindikat matul it-tqala (ara sezzjoni 4.3).
English: Each film-coated tablet contains 10 mg atorvastatin (as atorvastatin calcium trihydrate).
Maltese: Kull pillola miksija b'rita fiha 10 mg atorvastatin (bħala atorvastatin calcium trihydrate).
English: Each film-coated tablet contains 40 mg atorvastatin (as atorvastatin calcium trihydrate).
Maltese: Kull pillola miksija b'rita fiha 40 mg atorvastatin (bħala atorvastatin calcium trihydrate).
English: Each film-coated tablet contains 20 mg atorvastatin (as atorvastatin calcium trihydrate).
Maltese: Kull pillola miksija b'rita fiha 20 mg atorvastatin (bħala atorvastatin calcium trihydrate).
English: As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with atorvastatin and fusidic acid given concurrently.
Maltese: Bħal fi statins oħrajn, fl-esperjenza wara ttqegħid fis-suq, ġew irrappurtati avvenimenti relatati mal-muskoli, inkluż rhabdomyolysis, b'atorvastatin u fusidic acid mogħtija flimkien.
English: Patients were hypertensive, 40-79 years of age, with no previous myocardial infarction or treatment for angina, and with TC levels ≤6.5 mmol/l (251 mg/dl).
Maltese: TC ta' ≤6.5 mmol/l (251 mg/dl).
English: {PRODUCT NAME} is contraindicated in patients with active liver disease (see section 4.3).
Maltese: TAL-PRODOTT} hu kontraindikat f'pazjenti b'mard attiv fil-fwied (ara sezzjoni 4.3).
English: 40mg SD ↑ 35% Lower starting dose and clinical monitoring of these patients is recommended.
Maltese: 40mg SD ↑ 35% Hija rrakkomandata doża massima aktar baxxa u lmonitoraġġ kliniku ta' dawn ilpazjenti
English: Excipients
Maltese: Aterosklerożi
English: Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8).
Maltese: Ġew irrapportati każijiet eċċezzjonali ta' mard interstizjali tal-pulmuni b'xi statins, b'mod speċjali b'terapija fit-tul (ara sezzjoni 4.8).
English: In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD).
Maltese: Fl-istudju dwar il-Prevenzjoni tal-Puplesiji bi Tnaqqis Aggressiv fil-Livelli tal-Kolesterol (SPARCLStroke Prevention by Aggressive Reduction in Cholesterol Levels), l-effett ta' atorvastatin 80 mg kuljum jew plaċebo fuq il-puplesija ġie evalwat f'4731 pazjent li kellhom puplesija jew attakk iskemiku għal ftit ħin (TIA) fis-6 xhur ta' qabel u l-ebda storja ta' mard tal-qalb koronarju (CHD).
English: Paediatric: Pharmacokinetic data in the paediatric population are not available.
Maltese: Popolazzjoni tat-tfal: Mhix disponibbli dejta farmakokinetika mill-popolazzjoni tat-tfal.
English: In cases where co-administration of these medicinal products with atorvastatin cannot be avoided lower starting and maximum doses of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).
Maltese: Jekk ma tistax tiġi evitata l-amministrazzjoni fl-istess ħin, huwa rrakkomandat tnaqqis fid-doża u monitoraġġ kliniku għall-effikaċja (ara Tabella 1).
English: The recommended starting dose in this population is 10 mg of atorvastatin per day.
Maltese: Id-doża inizjali rrakkomandata f'din ilpopolazzjoni hija ta' 10 mg ta' atorvastatin kuljum.
English: Uncommon: hypoglycaemia, weight gain, anorexia
Maltese: Mhux komuni: ipogliċemija, żieda fil-piż, anoreksja
English: Co-administered medicinal product
Maltese: IL-PRODOTT MEDIĊINALI
English: When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly.
Maltese: Meta ngħataw flimkien dożi multipli ta' digoxin u 10 mg atorvastatin, il-konċentrazzjonijiet ta' digoxin fi stat stabbli żdiedu xi ftit.
English: Musculoskeletal and connective tissue disorders Common: myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain.
Maltese: Komuni: mijalġja, artralġja, uġigħ fl-estremitajiet, spażmi fil-muskoli, nefħa fil-ġogi, uġigħ fid-dahar.
English: There was significant treatment interaction by antihypertensive baseline therapy.
Maltese: Kien hemm interazzjoni sinifikanti tat-trattament bit-terapija bażika kontra l-pressjoni għolja.
English: Experience in paediatrics is limited to a small number of patients (age 4 - 17 years) with severe dyslipidemias, such as homozygous familial hypercholesterolemia.
Maltese: L-esperjenza fit-tfal hija limitata għal numru żgħir ta' pazjenti (li għandhom 4 - 17-il sena) b'dislipidemiji severi, bħal pereżempju iperkolesterolemija omozigota familjali.
English: • nausea, constipation, wind, indigestion, diarrhoea
Maltese: • dardir, stitikezza, gass, indiġestjoni, dijarea
English: In cases where coadministration with atorvastatin is necessary, do not exceed 10 mg atorvastatin daily.
Maltese: F'każijiet fejn l-għoti fl-istess ħin ta' atrovastatin huwa neċessarju, taqbiżx 10 mg atorvastatin kuljum.
English: Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with atorvastatin may result in increased exposure to atorvastatin.
Maltese: Kemm amiodarone kif ukoll verapamil huma magħrufin li jinibixxu attività ta' CYP3A4 u l-ko-amministrazzjoni ma' atorvastatin tista' tirriżulta f'żieda flespożizzjoni għal atorvastatin.
English: Very rare: hepatic failure.
Maltese: Rari ħafna: indeboliment tal-fwied.
English: For patients with prior hemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of hemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).
Maltese: Għal pazjenti li qabel kellhom attakk ta' puplesija b'emorraġija jew infart lakunari, il-bilanċ tar-riskji u l-benefiċċji ta' atrovastatin 80 mg mhuwiex ċert u rriskju potenzjali ta' puplesija b'emorraġija għandu jiġi kkunsidrat bir-reqqa qabel ma tinbeda l-kura (ara sezzjoni 5.1).
English: Atherosclerosis
Maltese: Puplesija rikorrenti
English: In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischemic attack (TIA) there was a higher incidence of hemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo.
Maltese: F'analiżi post-hoc ta' subtipi ta' puplesija f'pazjenti b'mard tal-qalb koronarju (CHD) li reċentement kellhom attakk ta' puplesija jew attakk iskemiku temporanju (TIA), kien hemm inċidenza ogħla ta' puplesija b'emorraġija f'pazjenti mibdija fuq atrovastatin 80 mg meta mqabbel ma' plaċebo.
English: The mechanism of this interaction is not known.
Maltese: Il-mekkaniżmu ta' din l-interazzjoni mhuwiex magħruf.
English: Thereafter, either the dose may be increased to a maximum of 80 mg daily or a bile acid sequestrant may be combined with 40 mg atorvastatin once daily.
Maltese: Minn hemm ‘l quddiem, id-doża jew tista' tiżdied sa massimu ta' 80 mg kuljum jew sekwestrant tal-aċidu biljari (bile acid) jista' jiġi kkombinat ma' 40 mg atorvastatin darba kuljum.
English: General disorders and administration site conditions Uncommon: malaise, asthenia, chest pain, peripheral oedema, fatigue, pyrexia.
Maltese: Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata Mhux komuni: telqa, astenja, uġigħ fis-sider, edema periferali, għeja, deni.
English: 40mg SD ↑ 3% Lower starting dose and clinical monitoring of these patients is recommended.
Maltese: 40mg SD ↑ 3% Hija rrakkomandata kemm doża massima aktar baxxa kif ukoll monitoraġġ kliniku ta' dawn ilpazjenti
English: • neck pain, muscle fatigue
Maltese: .8 Effetti mhux mixtieqa
English: Atorvastatin iiss effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.
Maltese: Atorvastatin huwa effikaċi biex inaqqas l-LDL-C f'pazjenti b'iperkolesterolemija omozigota familjali, popolazzjoni li ġeneralment ma rrispondietx għal prodotti mediċinali li jbaxxu l-lipidi.
English: If co-administration cannot be avoided, simultaneous coadministration of atorvastatin with rifampin is recommended, with clinical monitoring.
Maltese: Jekk l-għoti fl-istess ħin ma jistax ikun evitat, hija rrakkomandata lamministrazzjoni simultanja ta' atorvastatin ma' rifampin b'monitoraġġ kliniku.
English: ↓ less than
Maltese: Tiħux {ISEM
English: The risk might also be increased at concomitant administration of atorvastatin with other medicinal products that have a potential to induce myopathy, such as fibric acid derivates and ezetimibe (see section 4.4).
Maltese: Ir-riskju jista' jiżdied ukoll bl-għoti fl-istess ħin ta' atorvastatin ma' prodotti mediċinali oħra li għandhom il-potenzjal li jinduċu l-mijopatija, bħal pereżempju d-derivattivi ta' fibric acid u ezetimbe (ara sezzjoni 4.4).
English: Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy.
Maltese: L-għoti fl-istess ħin ta' prodotti mediċinali li huma inibituri ta' CYP3A4 jew proteini tal-ġarr jista' jwassal għal konċentrazzjonijiet ta' atorvastatin ogħla fil-plażma u aktar riskju ta' mijopatija.
English: ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole, rifampin, fusidic acid
Maltese: • rimettar, tifwiq, uġigħ fil-parti ta' fuq u ta' isfel taż-żaqq, pankreatite (infjammazzjoni tal-frixa li twassal għal uġigħ fl-istonku)